Physician profile
Gregory Hsu
NPI 1053871632
$2,889.17
in general payments reported to CMS, 2019-2025
19 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what 97% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.50 · 2023: $263 · 2024: $978 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,634 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,633.77 |
| Education | $237.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $796.64 | 2025 | Rapiblyk |
| Abiomed | $375.04 | 2024-2025 | Impella |
| Abbott Laboratories | $261.28 | 2024-2025 | Ensite, Cardiomems |
| Kestra Medical Technology Services, INC. | $233.71 | 2025 | Assure Wcd |
| Pfizer INC. | $205.93 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $173.98 | 2023-2024 | Inpefa |
| Teleflex LLC | $156.56 | 2025 | Guideliner |
| Janssen Pharmaceuticals, INC | $146.11 | 2023 | Xarelto |
| Amgen INC. | $145.41 | 2024-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $89.24 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $71.10 | 2023-2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $54.55 | 2023-2025 | Onpattro, Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $47.92 | 2024-2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.49 | 2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $30.56 | 2024 | Uptravi, Opsumit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $17.64 | 2025 | Farxiga |
| Glaxosmithkline, LLC. | $17.50 | 2021 | |
| Cordis US Corp. | $17.00 | 2024 | Mynx Control |
| Bayer Healthcare Pharmaceuticals INC. | $14.51 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.